Endocyte, Inc. (NASDAQ:ECYT) Files An 8-K Results of Operations and Financial ConditionItem 2.02 Results of Operations and Financial Condition.
On March 10, 2017, Endocyte, Inc. (the “Company”) announced its results of operations for the three months and full year ended December 31, 2016. A copy of the Company’s earnings release is furnished herewith as Exhibit 99.1.
Item 7.01 Regulation FD Disclosure.
On March 10, 2017, the Company issued a press release announcing its plan to collaborate with Seattle Children’s Research Institute and Dr. Michael Jensen for the development of Endocyte’s SMDC platform in the chimeric antigen receptor T-cell (CAR T-cell) immunotherapy setting through the use of Endocyte’s proprietary SMDC bi-specific adaptor molecules. A copy of the Company’s press release is furnished herewith as Exhibit 99.2.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
99.1 Earnings Release dated March 10, 2017
99.2 Press Release dated March 10, 2017
The information in this Current Report (including Exhibit 99.1 and Exhibit 99.2) is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Current Report (including Exhibit 99.1 and Exhibit 99.2) shall not be incorporated by reference into any registration statement or other document to the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.